Alphamab Oncology (9966) fair value: what the stock is really worth
We calculate from audited financials what Alphamab Oncology is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Alphamab Oncology for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range HK$2.12 – HK$27.75 · fair‑value band HK$0.7800 – HK$1.48 · the HK$7.73 price screens above the HK$1.18 fair value. Dashed = 300-day average. As of Sep 13, 2026.
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China.
Show more
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (BsAb) that is in Phase III clinical trials to treat HER2-positive breast cancer and HER2-positive gastric cancer or gastroesophageal junction cancer; KN046, a BsAb immune checkpoint inhibitor in Phase III clinical trial for the treatment of non-small cell lung cancer (NSCLC), squamous NSCLC, triple-negative breast cancer, and recurrent and metastatic esophageal squamous cell carcinoma; JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC) that is in Phase III clinical trial to treat HER2-expressing advanced or metastatic solid tumors, HER2-low expression breast cancer, platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer. In addition, the company is developing JSKN016, a bispecific ADC that is in Phase II clinical trial for the treatment of solid tumors, lung cancer, and breast cancer; JSKN022, a bispecific single-domain antibody; JSKN027, a bispecific ADC that is Phase I clinical trial; JSKN021; KN019; and JSKN033, a subcutaneous ADC in Phase I clinical trial to treat HER2-expressing advanced or metastatic solid tumors. The company also develops JSKN029, a pre-clinical stage product for oncology applications. Alphamab Oncology was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
Stock analysis
Alphamab Oncology (9966) currently trades at HK$7.73, while our model-based Fair Value estimate is HK$1.18, implying the stock looks roughly 554.5% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: HK$0.7800 (bear) to HK$1.48 (bull), the price of HK$7.73 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Alphamab Oncology reported revenue of 552M CNY in FY2025 versus 146M CNY in FY2021, a compound +39.4%/yr. Reported net income was −111M CNY in FY2025.
Key figures
Market cap HK$7.4B (≈ $947M) · P/S ratio 12.5 · EPS (TTM) HK$0.0200 · Net margin −20.1% · Return on equity −6.4% · Return on assets (EBIT) −10.4% · Operating margin −62.4% · Revenue (TTM) HK$566M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 51% below its 52-week high and 25% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −85%, 9966 screens richer than that median.
Fair Value models
Bear HK$0.7800Fair Value HK$1.18Bull HK$1.48
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (HK$0.0142 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.27/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−13.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+49.0%
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+114.7%
’17
’19
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−16,609.3% (2019) → −27.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks
Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score45 · Above median
Fair Value upside−87% · Bottom 25%
Profitability
Return on assets−4% · Above median
Net margin (TTM)−20% · Below median
Operating margin (TTM)−62% · Bottom 25%
Growth and dividend
Revenue growth−47% · Bottom 25%
Balance sheet
Debt / equity0.05× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B0.53× · Cheapest 25%
P/S (TTM)1.59× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)98· sector 97
DIVIDEND (yield)0· sector 24
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Alphamab Oncology Fair Value". https://www.fairvalue-calculator.com/stock/9966
Frequently asked questions
Is Alphamab Oncology (9966) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of HK$1.18 versus a price of HK$7.73, about −85% upside (overvalued).
What is the fair value of 9966?
Our model-based fair value for Alphamab Oncology is HK$1.18 (as of Sep 13, 2026), built from audited fundamentals. The current price: HK$7.73.
What is the quality score of 9966?
Alphamab Oncology has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Alphamab Oncology (9966)?
Our model-based price target is the fair value of HK$1.18 (as of Sep 13, 2026) from 1 valuation models. Cautious scenario HK$0.7800, optimistic scenario HK$1.48. It is a calculation from audited fundamentals, not an analyst target.
What is the Alphamab Oncology stock forecast for 2026?
Our models put fair value at HK$1.18, about −85% upside versus a price of HK$7.73 (overvalued). Cautious scenario HK$0.7800, optimistic scenario HK$1.48. The calculation is refreshed regularly with new filings.
What is the revenue of Alphamab Oncology (9966)?
Alphamab Oncology reported trailing-twelve-month revenue of about HK$566M (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of Alphamab Oncology (9966)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Alphamab Oncology it is HK$1.18 per share (as of Sep 13, 2026), against a price of HK$7.73. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Alphamab Oncology stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 9966 trades above its calculated fair value: price HK$7.73, fair value HK$1.18, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9966?
No. The price is what the market pays today (HK$7.73); the fair value is what the company's own numbers justify (HK$1.18). For Alphamab Oncology the two are HK$6.55 per share apart. That gap is exactly why we show both numbers side by side.
How much is Alphamab Oncology worth?
The market values Alphamab Oncology at about HK$7.4B (market capitalisation, as of Sep 13, 2026). Per share that is HK$7.73; our models calculate a fair value of HK$1.18 per share.
What do the bullish and bearish scenarios say about 9966?
Our models span a range for Alphamab Oncology: cautious scenario HK$0.7800, base HK$1.18, optimistic HK$1.48 per share (as of Sep 13, 2026, price HK$7.73). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Alphamab Oncology (9966)?
Balance-sheet figures for Alphamab Oncology (as of Sep 13, 2026): return on equity −6.4%, debt of 0.05 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 9966 from its 52-week high?
Alphamab Oncology trades at HK$7.73, about 51% below its 52-week high of HK$15.75 and 25% above the low of HK$6.16 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$1.18 is for.
Which stocks are comparable to Alphamab Oncology?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Alphamab Oncology stock attractive at the current price?
The data as of Sep 13, 2026: price HK$7.73, calculated fair value HK$1.18 (−85%), Quality Score 42/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9966 calculated?
We run Alphamab Oncology through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$1.18, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6 % above its aggregate fair value. Alphamab Oncology itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Alphamab Oncology (9966)?
The closing price on Sep 16, 2026 was HK$7.73. Our model-based fair value is HK$1.18, about −85% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Alphamab Oncology right now?
The price sits above even our optimistic bull case (HK$1.48). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (HK$0.7800 to HK$1.48) leaves room in how you read the outcome.
Key figures of Alphamab Oncology
How large is the market capitalisation of Alphamab Oncology (9966)?
The market capitalisation of Alphamab Oncology is HK$7.4B (≈ $947M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Alphamab Oncology (9966)?
The price-to-sales ratio of Alphamab Oncology is 12.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Alphamab Oncology (9966)?
Earnings per share at Alphamab Oncology are HK$0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Alphamab Oncology (9966)?
The net margin of Alphamab Oncology is −20.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Alphamab Oncology (9966)?
The return on equity (ROE) of Alphamab Oncology is −6.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Alphamab Oncology (9966)?
On an EBIT basis the return on assets of Alphamab Oncology is −10.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Alphamab Oncology (9966)?
The operating margin of Alphamab Oncology is −62.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Alphamab Oncology (9966)?
Revenue at Alphamab Oncology is growing −47.1% versus a year earlier (3y avg +49.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Alphamab Oncology (9966) generate?
The free cash flow of Alphamab Oncology is −HK$153M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Alphamab Oncology (9966) hold?
Alphamab Oncology holds more cash than debt, HK$136M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Alphamab Oncology in the live analysis
One click puts Alphamab Oncology on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
